The Recent US Preventive Services Task Force Guidelines Are Not Supported by the Scientific Evidence and Should Be Rescinded

Journal of the American College of Radiology

Volumn 7, Issue 4, 2010, Pages 260-264

  Kopans, Daniel B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Breast cancer; mammography screening; screening guidelines

Indexed keywords

BREAST CANCER; CANCER SCREENING; COMPUTER MODEL; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; MORTALITY; PRACTICE GUIDELINE; REVIEW;

EID: 84928095963     PISSN: 15461440     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacr.2009.12.008     Document Type: Review

References (31)

1. US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151 (2009) 716-726
2. American Cancer Society. Cancer statistics 2009 presentation. http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2009_Presentation.asp Accessed December 6, 2009
3. Kopans D.B. Beyond randomized, controlled trials: organized mammographic screening substantially reduces breast cancer mortality. Cancer 94 (2002) 580-581
4. Tabár L., Vitak B., Tony H.H., Yen M.F., Duffy S.W., and Smith R.A. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 91 (2001) 1724-1731
5. Duffy S.W., Tabár L., Chen H., et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 95 (2002) 458-469
6. Otto S.J., Fracheboud J., Looman C.W.N., et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361 (2003) 411-417
7. Michaelson J.S., Halpern E., and Kopans D.B. Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology 21 (1999) 551-560
8. Rosenquist C.J., and Lindfors K.K. Screening mammography in women aged 40-49 years: analysis of cost-effectiveness. Radiology 191 (1994) 647-650
9. Wald N.J., Murphy P., Major P., Parkes C., Townsend J., and Frost C. UKCCCR multicentre randomized controlled trial of one and two view mammography in breast cancer screening. BMJ 311 (1995) 1189-1193
10. Evans A.J., Kutt E., Record C., Waller M., and Moss S. Radiological findings of screen-detected cancers in a multi-centre randomized, controlled trial of mammographic screening in women from age 40 to 48 years. Clin Radiol 61 (2006) 784-788
11. Kopans D.B., and Feig S.A. The Canadian National Breast Screening Study: a critical review. AJR Am J Roentgenol 161 (1993) 755-760
12. Tarone R.E. The excess of patients with advanced breast cancers in young women screened with mammography in the Canadian National Breast Screening Study. Cancer 75 (1995) 997-1003
13. Kopans D.B. Informed decision making: age of 50 is arbitrary and has no demonstrated influence on breast cancer screening in women. AJR Am J Roentgenology 185 (2005) 177-182
14. Kopans D.B., Moore R.H., McCarthy K.A., et al. Biasing the interpretation of mammography screening data by age grouping: nothing changes abruptly at age 50. Breast J 4 (1998) 139-145
15. Kerlikowske K., Grady D., Barclay J., Sickles E.A., Eaton A., and Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270 (1993) 2444-2450
16. Shapiro S. Screening: assessment of current studies. Cancer 74 (1994) 231-238
17. Duffy S.W., Tabár L., and Smith R.A. The mammographic screening trials: commentary on the recent work by Olsen and Gøtzsche. CA Cancer J Clin 52 (2002) 68-71
18. Kopans D.B., Halpern E., and Hulka C.A. Statistical power in breast cancer screening trials and mortality reduction among women 40-49 with particular emphasis on the National Breast Screening Study of Canada. Cancer 74 (1994) 1196-1203
19. Hendrick R.E., Smith R.A., Rutledge J.H., and Smart C.R. Benefit of screening mammography in women ages 40-49: a new meta-analysis of randomized controlled trials. Monogr Natl Cancer Inst 22 (1997) 87-92
20. Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from organized service screening with mammography: 1Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 15 (2006) 45-51
21. Bjurstam N., Bjorneld L., Duffy S., et al. The Gothenburg Breast Cancer Screening Trial: preliminary results on breast cancer mortality for women ages 39-49. Monogr Natl Cancer Inst 22 (1997) 53-55
22. Andersson I., and Janzon L. Reduced breast cancer mortality in women under 50: update from the Malmo Mammographic Screening Program. Monogr Natl Cancer Inst 22 (1997) 63-67
23. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer 39 (1977) 2772-2778
24. Zahl P.H., Maehlen J., and Welch H.G. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 168 (2008) 2302-2303
25. Jørgensen K.J., and Gøtzsche P.C. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 339 (2009) b2587
26. Zackrisson S., Andersson I., Janzon L., Manjer J., and Garne J.P. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 332 (2006) 689-692
27. Duffy S.W., Agbaje O., Tabár L., et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 7 (2005) 258-265
28. Page D.L., Dupont W.D., Rogers L.W., Jenson R.A., and Schuyler P.A. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76 (1995) 1197-1200
29. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
30. Zahl P.H., and Maehlen J. A decline in breast-cancer incidence. N Engl J Med 357 (2007) 510-511
31. Seidman H., Stellman S.D., and Mushinski M.H. A different perspective on breast cancer risk factors: some implications of nonattributable risk. Cancer 32 (1982) 301-313